128 related articles for article (PubMed ID: 38049966)
21. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
22. Urinary Reflux Into the Prostate Gland and Seminal Vesicles: A Potential Pitfall in 18F-FDG and 68Ga-PSMA PET/CT.
Hekimsoy T; Gorur GD; Isgoren S; Uslu H; Demir H
Clin Nucl Med; 2020 Jul; 45(7):536-537. PubMed ID: 32433177
[TBL] [Abstract][Full Text] [Related]
23.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
24.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of
Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
[TBL] [Abstract][Full Text] [Related]
26. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
27. Unspecific
Seifert R; Telli T; Opitz M; Barbato F; Berliner C; Nader M; Umutlu L; Stuschke M; Hadaschik B; Herrmann K; Fendler WP
J Nucl Med; 2023 May; 64(5):738-743. PubMed ID: 36460340
[No Abstract] [Full Text] [Related]
28. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
[TBL] [Abstract][Full Text] [Related]
29. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
30.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
31.
Li Y; Wu X; Huang Y; Bian D; Jiang L
Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
[TBL] [Abstract][Full Text] [Related]
32. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
33. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer.
Tatar G; Ergül N; Baloğlu MC; Arslan E; Çermik TF
Clin Nucl Med; 2023 Mar; 48(3):e135-e137. PubMed ID: 36723899
[TBL] [Abstract][Full Text] [Related]
35. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
36.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
37. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
[TBL] [Abstract][Full Text] [Related]
38. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
39. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
40. Impact of uptake time on image quality of [
van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]